Articles related to Pediatrics

The FDA expanded the indication for olopatadine hydrochloride and mometasone furoate nasal spray to include children aged 6 to younger than 12 years with seasonal allergic rhinitis. Approval was supported by a phase 3 trial demonstrating improved nasal symptoms versus placebo.

Pediatric hearing loss care has shifted from physiologic detection and rehabilitation toward genetic diagnosis, prognostic counseling, and emerging targeted therapies. Advances in screening, cochlear implantation, and genetic testing have expanded etiologic evaluation, while therapeutic applications remain in early development.

Natural language processing models analyzing speech from children ages 9 to 13 predicted future mental health conditions more accurately than expert-rated stress assessments. Findings suggest linguistic patterns may serve as an early risk signal, though validation in larger cohorts is still needed.

U.S. News expanded its 2026-2027 hospital rankings with new regional specialty evaluations in cancer and cardiovascular care while increasing recognition for regional hospitals. Rankings continued to emphasize risk-adjusted mortality, preventable complications, patient experience, and objective outcomes measures.

The FDA approved centanafadine for ADHD in adults and children aged 6 years and older, introducing the first approved norepinephrine, dopamine, serotonin reuptake inhibitor for the disorder. Approval was based on phase 3 trial results and regulatory review.

Analysis of genetic testing data from nearly 180,000 individuals with autism suggests that Phelan-McDermid syndrome may affect approximately 1 in 7,300 people. The findings indicate the condition may be substantially more common than previously estimated and highlight ongoing diagnostic gaps.